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Abstract: Breast cancer is the most prevalent
cancer in women and an important cause of
both morbidity and mortality. Although longterm disease-free survival is offered to
women with early stage disease by current
treatment modality, some, 30-40% of
patients will have metastatic disease.
Treatment of patients with metastatic disease
is a great challenge for oncologists.
Therefore, new drugs and therapeutic options
for women with metastatic breast cancer are
urgently required.
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Arsenical compounds have cytotoxic effects on
several cancer cell lines including
promyelocytic
leukemia,
esophageal
carcinoma, megakaryocytic leukemia, and
malignant lymphocytic cell lines. In addition,
recent studies showed that arsenic trioxide
(As2O3) can induce a clinical remission in
patients with acute promyelocytic leukemia.

Introduction
Breast cancer accounts for 30% of all cancers in
women and still remains the leading cause of cancerrelated mortality in females (1). Metastatic breast cancer
(MBC) develops in 30-40% of patients with breast
carcinoma and is essentially incurable with standard
therapy. Patients with MBC have a median survival of
about 2 years (2,3) and, therefore, new anticancer agents
are urgently required.
Arsenical compounds have been used as anticancer
agents in traditional Chinese medicine. In the 1970s, the
effective component in the remedy was identified as
As2O3. Long-term clinical trials have indicated that As2O3
is effective for the treatment of several types of leukemia,
including APL (4,5). It has been shown that As2O3 can
induce clinical remission in patients with APL, including in
those who have relapsed after retinoic acid treatment (6).
However, the mechanism whereby As2O3 targets tumor
cells is not clearly understood. Several studies indicated
that As2O3 may be an oxidative agent that induces damage

In this study, we evaluated the cytotoxic
effects of arsenic trioxide (As2O3) alone and
combined with Taxane compounds (paclitaxel
and docetaxel) on human breast carcinoma
cell line MCF-7. It is clearly demonstrated that
As2O3 has a significant cytotoxic effect on
breast carcinoma cells. IC50 for As2O3 was 5 x
-6
10 M after 72 h. Apoptosis of carcinoma
cells was responsible for the cytotoxicity of
As2O3. The additive effects of taxane
compounds with As2O3 were shown. These in
vitro results may suggest that As2O3 is a
potential new cytotoxic agent for the
treatment of breast cancer.
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to DNA and causes DNA mutations (7). Ex vivo studies on
the APL cell line NB4 demonstrated that As2O3 downregulates Bcl-2 expression and induces apoptosis in the
absence of apparent differentiation (8). Moreover, a
recent study showed that As2O3 has a specific effect on
APL tumor cells by inducing the degradation of the
nuclear receptor for retinoic acid fusion protein. Although
As2O3 may display a specific biological action on APL
tumor cells, the apoptotic effect of As2O3 in leukemic cells
has led investigators to propose that As2O3 may also
induce apoptosis in other types of cancer cells.
Paclitaxel (PAC) and docetaxel (DOC) are clinically
effective antineoplastic agents and excellent choices for
the first- and second-line treatment of patients with MBC
(9-11). Taxanes bind to tubulin at the same site, retard
microtubule depolymerization, impair mitosis, and block
progression through the cell cycle. In addition, the
taxanes inactivate the Bcl-2 protein and induce apoptosis
in breast cancer cells in vitro (12,13).
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In patients with anthracycline-resistant MBC, PAC
produced response rates (RR) of 6% to 48%. As frontline therapy in patients not previously exposed to
chemotherapy, the RR were 32% to 62%. Several
different doses and schedules of paclitaxel have been
investigated and the regimen for optimal administration
has yet to be determined (14,15,16).
DOC is a highly effective agent for MBC. In previously
untreated patients, RR range from 40% - 68%, better
than any other single-agent chemotherapy (17,18). DOC
is particularly active in patients with anthracyclineresistant breast cancer (16).
Despite several attempts to improve further the
efficacy of current therapeutic options for patients with
MBC, no regimen until now has improved the chance of
cure. For this reason, in this study, we evaluated the
cytotoxic and apoptotic effects of a new candidate
cytotoxic compound, As2O3, alone and in combination
with taxanes on breast cancer cell line MCF-7 as a model
system.

Materials and Methods
Tumor Cells
The human breast carcinoma cell line MCF-7 was
kindly provided by Dr J.R. Bertino from the Memorial
Sloan-Kettering Cancer Center. MCF-7 cell line is
maintained in RPMI 1640 (Sigma Chemical Co., St. Louis,
Missouri) plus 10% heat inactivated fetal calf serum
(FCS) (Sigma Chemical Co., St. Louis, Missouri) added to
1% L-glutamine (Sigma Chemical Co., St. Louis,
Missouri), 1% non-essential amino acids (Sigma Chemical
Co., St. Louis, Missouri), 10,000 units/ml penicillin
(Sigma Chemical Co., St. Louis, Missouri), and 10 mg/ml
streptomycin (Sigma Chemical Co., St. Louis, Missouri) as
adherent cells. The cell line was grown in a humidified
atmosphere at 37 °C in 5% CO2. Tumor cells were used
as target cells; for this purpose, adherent cells were
treated with tyripsin-EDTA (Sigma Chemical Co., St.
Louis, Missouri), washed, and resuspended in complete
medium.
Reagents
As2O3 was kindly supplied by F. Lermioglu of Ege
University, School of Pharmacy, Izmir, Turkey. In its
lyophilized form, the 99.5% pure, inorganic compound
corresponds to the reported extracted drug used in
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Chinese herbal medicine. Paclitaxel, MTT, DMSO, and PBS
were purchased from Sigma Chemical Co. St. Louis,
Missouri. Docetaxel was kindly provided by W. Tong from
Memorial Sloan-Kettering Cancer Center, New York,
USA, at HPLC quality. Stock solutions of paclitaxel and
docetaxel were prepared in DMSO (Sigma Chemical Co.,
St. Louis, Missouri) and the DMSO concentration in the
assay did not exceed 0.1% and was not cytotoxic to MCF7 cells in comparison to media control.
The determination of doubling time of MCF-7
cells:
The trypan blue dye exclusion assay was used to
determine the doubling time of MCF-7 cells as described
previously (19). Each well of the six well plates included
5 x 105 cells in duplicate with control and total volume
was made to 2 ml with medium. The plates were
incubated in a humidified 5% CO2 atmosphere. Cell
viability was determined at 24, 48, 72, and 96 h.
Cytotoxicity Assay
The trypan blue dye exclusion test was used to
determine drug-mediated cytotoxicity as described
previously. Briefly, 25 x 104 target tumor cells were
resuspended in 1 ml. Two ml of cell suspension were
distributed into each well of a 6-well plate, and then a 2
ml reagent solution or medium at the desired
concentration was added into each well. Each plate was
incubated for 72 h at 37 °C and 5% CO2 atmosphere.
Following the incubations, 100 µl of the trypan blue dye
was added into 100 µl of cell suspension. After this
process, viable and dead cells were counted. The
percentage of cytotoxicity was calculated as follows:
(%) cytotoxicity = 100 – [100 x (total cell number in
the experimental well / total cell number in the control
well)]
Assays were performed at least three times.
DNA fragment detection by ELISA
A cell death detection ELISA kit (Cell Death Detection
ELISAplus; Boehringer Manheim, Germany) was used
according to the manufacturer’s instructions for the DNA
fragments detection (20). The principle of this test is
based on the detection of mono-and oligo-nucleosomes in
the cytoplasmic fractions of cell lysates by using
biotinylated antihiston- and peroxidase-coupled anti-DNA
antibodies. Enrichment factor is used as a parameter of
apoptosis and is shown on the y-axis as mean ± standard
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deviation (SD) of triplicates. Assays are performed at
least three times, and data shown are representatives of
those assays.

MCF-7 (Arsenic trioxide)
2.5

Results
Doubling time of MCF-7 cells
The doubling time of MCF 7 cells was 72 h.
The determination of cytotoxicity with As2O3, PAC
and DOC on the MCF-7 breast cancer cell line:

Enrichment factor

2

1.5

1
0.5

1. IC50 concentration of As2O3
The stock solution of As2O3 was prepared as 1 x 10-3
M and final concentrations were planned to be 1 x 10-6,
2 x 10-6, 5 x 10-6, 8 x 10-6, and 1 x 10-3 M. For each
concentration, cell viability was determined after 72 h
incubation. IC50 value for As2O3 was 5 x 10-6 M (Figure
1).

MCF-7 (Arsenic trioxide)

0
Control

Figure 2.
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Concentration (M)

8 x 10-6

As2O2–induced apoptosis in human breast cancer cell line
MCF-7. Cells were treated with different concentrations of
As2O3 for 24 h. Apoptosis was examined by determining
nucleosomal DNA fragmentation using an apoptosis
determination kit. Rate of apoptosis is reflected by
enrichment of nucleosomes in the cytoplasm shown on the
y-axis. Data presented show one representative of three
independently performed experiments.
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3. IC50 concentrations of PAC and DOC
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80

PAC and DOC were prepared as 40 ng/ml stock
solution and final concentrations were 2.5, 5, 10, 15, and
20 ng /ml. For each concentration, cell viability was
determined after 72 h incubation. IC50 value for PAC was
10 ng/ml and for DOC was 5 ng/ml (Figures 3 and 4).
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4. The Cytotoxic Effect of As2O3 in Combination
with Taxanes on MCF-7 Breast Carcinoma Cell Line
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Figure 1.

Cytotoxicity of tumor cells treated with different
concentrations of As2O3. Cytotoxicity was assessed by the
trypan blue dye exclusion test following 72 h culture. The
data represent the mean of three different experiments with
SD not exceeding 5%.

Figures 5 and 6 present data related to the combined
effects of As2O3 with PAC and DOC on MCF-7 cells. The
graphs in Figures 5 and 6 clearly show that the effects of
these combined drugs were additive and not synergistic.
The data suggest that no dose lowering is possible with
the combined As2O3 regimens, but these agents can be
used in combination for an augmented cytotoxic effect in
the treatment of breast cancer.

2. The apoptotic effect of As2O3 on MCF-7 cells
To evaluate the induction of apoptosis of breast
carcinoma cells by As2O3, the cell suspensions were
treated by various concentrations of As2O3. Mono- and
oligo- nucleosomes were measured. It was shown that
the enrichment factor of mono- and oligo-nucleosomes
increased in correlation with the increasing
concentrations of As2O3 (Figure 2 ).

Discussion
Several in vitro and clinical investigations clearly
showed that As2O3 has a strong potential usage in
different types of cancer treatment. Our only clinical
experience was with patients with acute promyelocytic
leukemia; there is strong investigational evidence that
show its potent cytotoxic effects on different cancer cell
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Figure 3 and 4. Cytotoxic effects of paclitaxel and docetaxel on MCF-7 cells. Cytotoxicity was assessed by the trypan blue dye exclusion test following
72 h culture. The data represent the mean of three different experiments with SD not exceeding 5%.
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Cytotoxicity analysis of treatment with combination of
As2O3 and paclitaxel of MCF-7 cells. Cytotoxicity was
determined by the trypan blue dye exclusion test in a 72 h
culture. The results are expressed as the mean of three
different experiments (SD < 5).

lines in vitro. In this study, we have evaluated the
cytotoxic effect of As2O3 on the MCF-7 breast cancer
cancer line. We have selected this cell line as a model
system because of clinical requirements for the better
treatment of metastatic breast carcinoma. As2O3 exerts
an important cytotoxicity on MCF-7 cells. The major
underlying mechanism of its cytotoxicity seems to be the
induction of cell apoptosis. The cytotoxic effects of As2O3
in combination with two well-known active agents, PAC
and DOC, were also investigated. Both PAC and DOC are
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Cytotoxicity analysis of treatment with combination of
As2O3 and docetaxel of MCF-7 cells. Cytotoxicity was
determined by the trypan blue dye exclusion test in a 72 h
culture. The results are expressed as the mean of three
different experiments (SD < 5).

very active agents and have been widely used clinically. In
combination with either of the taxanes additive effects
were found. No synergism between As2O3 and taxanes
was investigated.
The effective cytotoxic dose of As2O3 (IC50 5nM) on
MCF-7 cells was found to be in the range of acceptable
clinical dose levels. In patients with APL, plasma levels
were about 10nM and this level was very well tolerated.
Although the precise mechanism of arsenic trioxide
action is unknown, a variety of in vitro studies suggest
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that several mechanisms may contribute to its
effectiveness in vivo. These mechanisms include induction
of apoptosis, partial cellular differentiation, degradation
of specific APL fusion transcripts, antiproliferation, and
inhibition of angiogenesis (4).

tumors, all of them include in vitro studies. Our group
reported that arsenic trioxide has a cytotoxic effect on
ovarian and prostate cancer cell lines (22). As2O3 has also
been reported to be effective on cervical cancer (23),
bladder cancer (24), and esophageal cancer (25) cell lines.

It has been shown that in certain leukemia cell lines,
thiol diester bonds were lysed by As2O3, and that was the
main mechanism underlying cytotoxicity (5). As2O3 may
also induce its apoptotic effects by means of its
interaction with the cytoskeleton and tubuli system of the
cell, which has been reported in leukemic cell lines (21).
In APL, it has been shown that As2O3 degrades abnormal
PML-RARa fusion protein and induces Bcl-2 downregulation (8).

In conclusion, the results presented in this report
indicate that As2O3 is cytotoxic on breast cancer cells.
Paclitaxel and docetaxel showed promising effects in
combination with As2O3, and clinical trials with these
combinations are warranted.

As2O3 has mostly been used in hematological
malignancies. Especially, As2O3 is used in APL treatment
refractory to other treatment modalities. There are
limited data about the cytotoxicity of As2O3 on solid
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